The antiinflammatory action of glucocorticoids is mediated partly by the inhibition of the expression of several cytokines and adhesion molecules. Some activators for nuclear receptors other than the GR have also been shown to inhibit the expression of these inflammatory molecules, although their molecular mechanisms remain unidentified. We therefore ex- 
I N VASCULAR ENDOTHELIAL cells (ECs) the expression
of several cytokines and cell adhesion molecules is upregulated in response to proinflammatory cytokines such as TNF␣ and IL-1. This up-regulation represents part of the inflammatory process affecting vascular walls (1) (2) (3) . To inhibit the expression of these inflammatory molecules is therefore one of the targets of antiinflammatory drugs. Glucocorticoids are thought to exert their antiinflammatory effects at least partly through inhibiting the expression of many cytokines, including TNF␣ (4), IL-2 (5), IL-3 (6), IL-5 (7), , and IL-8 (9) . Furthermore, in the case of vascular ECs glucocorticoids reportedly have a direct inhibitory effect on the expression of adhesion molecules such as intercellular adhesion molecule-1 (10), E-selectin (10, 11) , and vascular cell adhesion molecule-1 (VCAM-1) (12) . Recent observations indicate that the GR can repress the gene transcription of these inflammatory molecules by interaction with transcription factors such as activating protein-1 (13) (14) (15) and nuclear factor-B (NF-B) (11, 16 -19) .
Recently, other nuclear receptor activators, such as estrogens (20, 21) , progestins (22) , retinoic acids (23) , and fibric acid derivatives (24) , have also been shown to inhibit the expression of several adhesion molecules in cultured vascular ECs. These results suggest the potential basis that these nuclear receptor activators use to exert their biological effects at inflammatory sites on vascular walls in atherosclerosis and cutaneous vascular diseases. There is little information, however, about the precise molecular mechanisms by which these nuclear receptor activators inhibit the expression of adhesion molecules in vascular ECs. Several studies have indicated that the transcriptional inhibition of the adhesion molecules is the result of the inhibition of NF-B activity by the nuclear receptor activators (22) (23) (24) .
NF-B is a widely expressed transcription factor that has a positive regulatory effect on the expression of genes for several cytokines and cell adhesion molecules (25) . It is a dimer that typically comprises p65 (RelA) and p50 subunit (26) . In its unactivated form, NF-B is retained in the cytoplasm through interaction with the inhibitory protein IB (26) . When cells are stimulated with extracellular signals such as a proinflammatory cytokine and an oxidative stressor, NF-B is activated through phosphorylation and ubiquitination of IB (inhibitor of NF-B), leading to proteolytic degradation (26) . Subsequently, NF-B is released from the inhibitory protein and migrates to the nucleus, where it activates transcription of target genes.
The promoters of both the IL-6 gene and the VCAM-1 gene contain binding sites for NF-B, although the nucleotide sequences of these promoters are not exactly the same (27, 28) . In the study presented here, we examined the effects of the PPAR␣ activator and the GR activator on the expression of IL-6 and VCAM-1 in human vascular ECs.
Materials and Methods

Cell culture and materials
Human umbilical vein endothelial cells (HUVECs: Cascade Biologics, Portland, OR) were maintained in MCDB131 medium with 10% FBS (JRH Biosciences, Lenexa, KS) and 2 ng/ml basic fibroblast growth factor (bFGF; Kaken Pharmaceutical, Osaka, Japan; growth medium). Bovine aortic endothelial cells (BAECs; Cell Systems, Kirland, WA) were grown in DMEM with 10% FBS. Human TNF␣ was obtained from Dainippon Pharmaceutical (Osaka, Japan). Fenofibrate was obtained from Kaken Pharmaceutical. Pioglitazone was purchased from Takeda Pharmaceutical (Osaka, Japan). Dexamethasone was obtained from Sigma (St. Louis, MO). RU486 was purchased from BIOMOL Research Laboratories, Inc. (Plymouth Meeting, PA).
Immunocytochemistry
After treatment with acetone/methanol (1:1, vol/vol), HUVECs were incubated with rabbit antibody against GR or goat antibody against PPAR␣ (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) diluted 1:100, followed by incubation with FITC-conjugated second antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) or Cy3-conjugated second antibody (Jackson ImmunoResearch Laboratories, Inc.), respectively. The specimens were examined with an Axiovert 135 fluorescent microscope equipped with LSM410 confocal microscopy (Carl Zeiss, Jena, Germany).
For immunostaining of NF-B p65 protein, 2% paraformaldehydetreated HUVECs were incubated with 5% goat serum in PBS for 1 h and then with antibody against p65 (Santa Cruz Biotechnology, Inc.) diluted 1:200, followed by incubation with biotinylated antirabbit IgG antibody. The next steps were performed with the use of Vectastain ABC kit (Vector Laboratories, Inc., Burlingame, CA).
Determination of secreted IL-6
HUVECs were plated onto 96-well collagen-coated dishes (2 ϫ 10 4 cells/well) in the growth medium. The next day, the culture medium was replaced by MCDB131-10% FBS without bFGF. The cells were treated with test compounds or vehicle (0.1% dimethylsulfoxide) for 24 h and thereafter were stimulated with 20 ng/ml TNF␣ for 24 h. Culture supernatants were collected and centrifuged at 1500 rpm for 5 min to remove any particulate material. Human IL-6 concentrations in the culture supernatants were determined by ELISA (kit from R & D Systems, Minneapolis, MN).
Determination of cell surface adhesion molecules
HUVECs were plated onto 96-well collagen-coated dishes (2 ϫ 10 4 cells/well) in the growth medium. The next day, the culture medium was replaced by MCDB131-10% FBS without bFGF. Then the cells were treated with test compounds or vehicle (0.1% dimethylsulfoxide) for 24 h and thereafter were stimulated with 20 ng/ml TNF␣ for 4 h. ELISA for cell surface VCAM-1 was performed as described previously (22) .
Transient transfection
To investigate the effect of test compounds on IL-6 and VCAM-1 promoter activities, we transiently transfected BAECs with an IL-6 or a VCAM-1 reporter construct. The IL-6 reporter, provided by Dr. S. Akira (Osaka University, Osaka, Japan), consists of 5Ј-flanking region (Ϫ840/ ϩ12) of the human IL-6 gene and firefly luciferase. The VCAM-1 reporter, provided by Dr. M. Kurabayashi (Gunma University, Maebashi, Japan), consists of 5Ј-flanking region (Ϫ258/ϩ40) of the human VCAM-1 gene and firefly luciferase. BAECs on 24-well plates were transfected with each of the reporter plasmids (1 g) together with seapansy luciferase control plasmid (0.1 g; Toyo Beanet, Tokyo, Japan) using SuperFect Transfection Reagent (QIAGEN, Valencia, CA). Two hours after the transfection, the cells were treated for 24 h with test compounds and subsequently with 20 ng/ml TNF␣. The cell lysates were assayed for each luciferase activity in Lumat LB9501 luminometer (Berthold Systems, Aliquippa, PA).
In some experiments to investigate the effects of dexamethasone on these promoter activities, 4 ng of the human GR expression vector pRShGR␣ (provided by Dr. K. Umesono) (29) together with an IL-6-or a VCAM-1-reporter construct were transfected into BAECs. Four hours after the transfection, the cells were treated with test compounds as described above.
Nuclear extraction and EMSA
HUVECs were treated with test compounds, and thereafter were stimulated with TNF␣ as described above. The nuclear extracts were prepared by the method of Schreiber et al. (30) . EMSA for NF-B was performed as we described previously (31) . The sequence of double stranded oligonucleotides used was 5Ј-CATGGGAAAATCCCA-CATTT-3Ј for the human IL-6 gene promoter (27) and 5Ј-CTGCCCT-GGGTTTCCCCTTGAAGGGATTTCCCT-CCGCC-3Ј for the human VCAM-1 gene promoter (28) . The NF-B binding consensus sequence is underlined.
Statistics
The data were analyzed by ANOVA, and the Bonferroni method was used to estimate the level of significance of differences between means. P Ͻ 0.05 was considered statistically significant.
Results
Expression of PPAR␣ and GR in human vascular ECs
Immunofluorescence staining revealed that PPAR␣ was localized predominantly to the cytoplasm in HUVECs (Fig.  1 ). When the cells were treated with fenofibrate, PPAR␣ staining was observed in the nuclei (Fig. 1 ). In contrast, GR was localized in the nuclei of the cells regardless of whether the cells were treated with dexamethasone ( Fig. 1) . Staining was specific for each of the nuclear receptors, as the staining was blocked by each of their antibodies subjected to preabsorption with excess antigen (data not shown).
Effects of fenofibrate and dexamethasone on TNF␣-induced IL-6 production in human vascular ECs
When HUVECs were treated with TNF␣, the IL-6 concentration in the culture supernatants was increased to about 3-fold. TNF␣-induced IL-6 production was inhibited by treatment with fenofibrate in a concentration-dependent manner ( Fig. 2A) : At 5 ϫ 10 Ϫ5 m or more, fenofibrate showed significant inhibition of IL-6 production. Treatment with fenofibrate alone (10 Ϫ4 m) had no significant effect on IL-6 production, whereas the PPAR␥ activator pioglitazone (10 Ϫ4 m) showed no apparent inhibitory effect on TNF␣-induced IL-6 production ( Fig. 2A) . Dexamethasone at 10 Ϫ9 m or more showed significant inhibition of TNF␣-induced IL-6 production in a concentration-dependent manner, but it did not affect basal IL-6 levels (Fig. 2B) . The GR antagonist RU486 (10 Ϫ5 m) prevented the dexamethasone (10 Ϫ7 m)-induced inhibition of TNF␣-stimulated IL-6 production (Fig. 2B) .
Effects of fenofibrate and dexamethasone on TNF␣-induced VCAM-1 expression in human vascular ECs
Next, we examined the effects of fenofibrate and dexamethasone on TNF␣-induced cell surface VCAM-1 expression in HUVECs. As shown in Fig. 3A , fenofibrate inhibited TNF␣-induced VCAM-1 expression in a concentrationdependent manner, with its inhibitory effect becoming noticeable at 10 Ϫ4 m or more. Pioglitazone (10 Ϫ4 m) had no effect on the TNF␣-induced VCAM-1 levels. Dexamethasone also had no effect on the TNF␣-induced VCAM-1 levels even when the cells were treated with 10 Ϫ5 m dexamethasone (Fig. 3B) .
Effects of fenofibrate and dexamethasone on IL-6 and VCAM-1 promoter activities in bovine vascular ECs
To determine whether fenofibrate inhibits IL-6 and VCAM-1 gene expression at transcription levels, we performed transient transfection assay. BAECs were used for this purpose, because these cells were found to be more suitable for transfection than HUVECs. TNF␣ increased IL-6 promoter activity by 16-fold compared with that in unstimulated cells (Fig. 4A) . Treatments with fenofibrate concentrations of 5 ϫ 10 Ϫ5 m or more significantly reduced the TNF␣-induced IL-6 promoter activity, whereas fenofibrate alone had no significant effect on basal IL-6 promoter activity. As shown in Fig. 4B , TNF␣ also enhanced VCAM-1 promoter activity by 20-fold in BAECs. Fenofibrate at concentrations of 5 ϫ 10 Ϫ5 m or more clearly inhibited VCAM-1 promoter activity.
In the next experiments we investigated the effects of dexamethasone on promoter activities of IL-6 and VCAM-1 genes. Transient transfection analysis in BAECs revealed that dexamethasone failed to suppress the TNF␣-stimulated promoter activity of either gene. As Inoue et al. (32) demonstrated that these cells express GR at a low levels, we introduced a GR expression vector into these cells. In BAECs transfected with this vector, dexamethasone (10 Ϫ7 m) significantly inhibited the TNF␣-induced IL-6 promoter activity (Fig. 5A) , but failed to inhibit the TNF␣-induced VCAM-1 promoter activity (Fig. 5B) .
Effects of fenofibrate and dexamethasone on NF-B binding to its recognition sites in IL-6 and VCAM-1 promoter regions
To investigate whether fenofibrate and dexamethasone affect NF-B binding to its recognition sites in IL-6 as well as VCAM-1 promoters, EMSAs were performed using nuclear extracts from HUVECs and radiolabeled oligonucleotide probes corresponding to the NF-B binding sites in the promoters of the two genes. The EMSA using oligonucleotides for the IL-6 gene demonstrated that fenofibrate (10 Ϫ4 m) as well as dexamethasone (10 Ϫ7 m) reduced the amount of gelretarded complexes induced by TNF␣ (Fig. 6A) . The EMSA using oligonucleotides for VCAM-1 gene, however, demonstrated that fenofibrate, but not dexamethasone, reduced the amount of gel-retarded complexes induced by TNF␣ (Fig.  6B) . Pioglitazone elicited no change in the gel-retarded complexes in either EMSA (Fig. 6, A and B) . The TNF␣-induced NF-B complexes consisted mainly of p65 (RelA) and p50, as evidenced by the supershifted bands resulting from the addition of p65 antibody and/or p50 antibody (Fig. 6, A and B) . 
Effects of fenofibrate and dexamethasone on nuclear translocation of NF-B in human vascular ECs
Nuclear translocation of the NF-B dimer from cytoplasms is a prerequisite for activation of NF-B (26) . Thus, we investigated the effects of fenofibrate and dexamethasone on the cellular localization of the NF-B p65 protein. As shown in Fig. 7 , TNF␣ stimulated translocation of the p65 protein from cytoplasms to nuclei in HUVECs, whereas neither fenofibrate (10 Ϫ4 m) nor dexamethasone (10 Ϫ7 m) could prevent this translocation.
Discussion
The expression of PPAR␣ in human vascular ECs was previously demonstrated by RT-PCR and Western blot analyses (33, 34) . In this study we showed for the first time that PPAR␣ is localized predominantly to cytoplasms in HUVECs and is translocated into nuclei upon stimulation with the PPAR␣ activator fenofibrate. PPAR␥1 mRNA is also expressed in human vascular ECs (35, 36) . We therefore compared the effects of the pharmacological activators of PPAR␣, PPAR␥, and GR on the expression of the known key molecules in vascular inflammation, IL-6 and VCAM-1, in HUVECs. Our results showed that the PPAR␣ activator fenofibrate clearly inhibits TNF␣-stimulated IL-6 production, but the PPAR␥ activator pioglitazone does not. In this connection, Staels et al. (37) have recently shown that PPAR␣ activators, but not PPAR␥ activators, inhibit IL-1-mediated IL-6 production in vascular smooth muscle cells. Then two sets of results mean that PPAR␣ acts as a down-regulator of IL-6 production in both vascular endothelial cells and vascular smooth muscle cells. In our experiments the GR activator dexamethasone also inhibited TNF␣-induced IL-6 production in HUVECs, and this inhibition was completely restored by the GR antagonist RU486, indicating that it is mediated by GR. IL-6 is known to control macrophage and T cell activation as well as vascular smooth muscle cell proliferation (38, 39) and has been detected in human and rabbit atherosclerotic regions (40, 41) . Therefore, the inhibition of IL-6 production in vascular ECs may contribute to the antiinflammatory effects of PPAR␣ and GR on vascular walls. VCAM-1 has been shown to play an important role in mediating mononuclear leukocyte-selective adhesion to vascular endothelium (3, 42) . This is expressed in vascular inflammatory disorders such as atherosclerosis, vasculitis, renal diseases, arthritis, and graft resection (3, 43) , and its soluble form is elevated in sera from patients with such diseases (44 -46) , indicating that VCAM-1 is one of the key molecules involved in vascular inflammatory disorders. This means that this adhesion molecule also is a molecular target of antiinflammatory drugs in vascular walls. Furthermore, our study showed that fenofibrate inhibits TNF␣-induced VCAM-1 expression in HUVECs, but that pioglitazone does not. These results support the findings obtained by using human saphenous vein ECs (24) . Very interestingly, however, dexamethasone failed to inhibit the TNF␣-induced VCAM-1 expression in HUVECs. Thus, PPAR␣ proved to have inhibitory effects on both IL-6 and VCAM-1 expression in the human vascular ECs, but GR inhibited only IL-6 expression.
As suggested by the experiments involving transient transfection of an IL-6 or a VCAM-1 promoter construct, the inhibitory effects of fenofibrate on both IL-6 and VCAM-1 expression may be exerted at least partly as a result of transcriptional inhibition of these genes. In experiments using BAECs transfected with human GR expression vector, on the other hand, dexamethasone only reduced IL-6 promoter activity, not VCAM-1 promoter activity. Thus, PPAR␣ and GR had similar effects on the inhibition of the IL-6 gene promoter, but different effects on the VCAM-1 gene promoter in vascular ECs.
Both of the genes encoding IL-6 and VCAM-1 are known to have NF-B-binding sites in their promoter regions (27, 28) . In our EMSA using oligonucleotide probes derived from the human IL-6 gene promoter, fenofibrate as well as dexamethasone clearly suppressed TNF␣-activated NF-B binding. By contrast, in the EMSA using oligonucleotide probes from the human VCAM-1 gene promoter, only fenofibrate inhibited such binding. Thus, the differences in the effects of fenofibrate and dexamethasone on NF-B binding to the two promoters correlate to those on protein expression and promoter activity. The totality of these findings suggests that the inhibition of both IL-6 and VCAM-1 expression by fenofibrate as well as the inhibition of IL-6 expression by dexamethasone are mediated at least in part through interference with NF-B activity. The TNF␣-stimulated NF-B proteins consist mainly of p65 (RelA) and p50 (NF-B1) in HUVECs. Immunocytochemical analysis demonstrated that neither fenofibrate nor dexamethasone prevented nuclear translocation of the p65 protein. Thus, the inhibitory effects of fenofibrate and dexamethasone on NF-B binding must be exerted chiefly during stages after the nuclear translocation of NF-B. In contrast to our findings, Simoncini et al. (47) have shown that nuclear translocation of both p50 and p65 after LPS treatment was inhibited by dexamethasone in human saphenous vein ECs. Although the reason for this discrepancy is not clear, differences in the sources of vascular ECs or in the stimulators for NF-B may be responsible. In this connection, Brostjan et al. (18) have shown that although IB␣-dependent down-regulation of NF-B activity by glucocorticoids has been postulated (48, 49) , such a mechanism is not involved in vascular endothelial cells.
The molecular mechanisms of interference of NF-B ac- tivity by PPAR␣ and GR remain unidentified. Studies using overexpression systems have shown that GR can be physically associated with p65 protein, thereby antagonizing it (16, 17) . In similar experimental systems, both ER (50) and PR (51) have been shown to be capable of physical association with the p65 protein. Delerive et al. (52) have recently shown that in glutathione-S-transferase pull-down experiments PPAR␣ also physically interacts with p65. In view of these findings in overexpression systems, physical interaction between these nuclear receptors and NF-B proteins might also occur physiologically in vascular ECs. We therefore propose a hypothesis of down-regulation of NF-B activity by PPAR␣ and GR via their interaction with NF-B in vascular ECs. As one of the reasons for target gene-specific downregulation of NF-B activity by PPAR␣ and GR, it has been suggested that repression of gene transcription by nuclear receptors can result from competition for limited amounts of coactivators (53, 54). If such a competition model is responsible for the target gene-specific down-regulation of NF-B, the predominant coactivator(s) involved in PPAR␣-and GR-mediated gene repression may be different. Alternatively, coactivators may not be involved in the mechanisms by which PPAR␣ and GR exert their specific repression of NF-B-driven genes. In this connection, it has been shown that overexpression of the coactivator cAMP-responsive element-binding protein-binding protein does not relieve PPAR␣-mediated transcriptional repression of p65 (52). Furthermore, a recent study (55) has shown that cAMP-responsive element-binding proteinbinding protein functions as an integrator of GR/p65 physical interaction, rather than as a limiting cofactor for which GR and p65 compete. On the other hand, De Bosscher et al. (56) recently proposed a model in which glucocorticoids repress NF-B-driven genes by interfering with the interaction of p65 with the basal transcription machinery. The sum total of these finding suggests that the repression of NF-B-driven genes by PPAR␣ or GR in vascular ECs may be evoked in a specific interaction of the nuclear receptor, NF-B, coactivator(s), and/or some components of the basal transcription machinery, which may, in turn, be responsible for the target gene-specific downmodulation of NF-B activity by the nuclear receptor.
Down-regulation of IL-6 and VCAM-1 gene expression on vascular walls may lead to important clinical consequences, as these molecules are involved in the pathogenesis of various inflammatory disorders. In the study presented here we showed that the PPAR␣ activator fenofibrate has a more beneficial effect than the GR activator dexamethasone on the expression of IL-6 and VCAM-1 in vascular ECs. Thus, this PPAR␣ activator may have the potential to relieve vascular inflammation, sometimes even more effectively than glucocorticoids. dexamethasone (Dex), they were stimulated, or not, with 20 ng/ml TNF␣ for 4 h. These cells were stained with NF-B p65 antibody. Three independent experiments produced similar results.
